These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20226481)

  • 1. [Pentosidine: a new biomarker in diabetes mellitus complications].
    Morales S; García-Salcedo JA; Muñoz-Torres M
    Med Clin (Barc); 2011 Mar; 136(7):298-302. PubMed ID: 20226481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Müller UA; Stein G
    Eur J Med Res; 2004 Aug; 9(8):391-9. PubMed ID: 15337629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes.
    Miura J; Yamamoto Y; Osawa M; Watanabe T; Yonekura H; Uchigata Y; Yamamoto H; Iwamoto Y
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):253-4. PubMed ID: 17185626
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced carbonyl stress in a subpopulation of schizophrenia.
    Arai M; Yuzawa H; Nohara I; Ohnishi T; Obata N; Iwayama Y; Haga S; Toyota T; Ujike H; Arai M; Ichikawa T; Nishida A; Tanaka Y; Furukawa A; Aikawa Y; Kuroda O; Niizato K; Izawa R; Nakamura K; Mori N; Matsuzawa D; Hashimoto K; Iyo M; Sora I; Matsushita M; Okazaki Y; Yoshikawa T; Miyata T; Itokawa M
    Arch Gen Psychiatry; 2010 Jun; 67(6):589-97. PubMed ID: 20530008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M; Franke S; Stein G; Wolf G;
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
    Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
    Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.
    Horie K; Miyata T; Maeda K; Miyata S; Sugiyama S; Sakai H; van Ypersole de Strihou C; Monnier VM; Witztum JL; Kurokawa K
    J Clin Invest; 1997 Dec; 100(12):2995-3004. PubMed ID: 9399945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke.
    Ikeda T; Maruyama K; Ito N; Utagawa A; Nagane M; Shiokawa Y
    J Stroke Cerebrovasc Dis; 2012 Jul; 21(5):386-90. PubMed ID: 21111635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased concentrations of serum pentosidine in rheumatoid arthritis.
    Rodríguez-García J; Requena JR; Rodríguez-Segade S
    Clin Chem; 1998 Feb; 44(2):250-5. PubMed ID: 9474020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
    Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
    Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients.
    Nur E; Brandjes DP; Schnog JJ; Otten HM; Fijnvandraat K; Schalkwijk CG; Biemond BJ;
    Br J Haematol; 2010 Oct; 151(1):62-9. PubMed ID: 20678158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE; Michel PL; Gillery P; Jaisson S; Fonfrede M; Morel F; Hartemann A; Bourron O
    Diabetes Metab Res Rev; 2014 Nov; 30(8):679-85. PubMed ID: 24449227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
    Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
    Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.